Literature DB >> 3495696

Intralymphatic interleukin-2 treatment of a hemophiliac AIDS patient with defective interleukin-2 production.

M Gramatzki, G R Burmester, N Heyder, H G Nüsslein, W Rödl, W Grote, D A Monner, P F Mühlradt, J R Kalden.   

Abstract

To improve immune functions in an interleukin-2 (IL-2) deficient hemophiliac AIDS patient suffering from severe Pneumocystis carinii pneumonia, treatment with IL-2 was started in addition to standard antimicrobial therapy. Highly purified IL-2 was administered subcutaneously and then repeatedly intralymphatically in a manner similar to pedal lymphography. No toxicity was observed. The patient temporarily improved clinically as well as with regard to immunological functions. Particularly the in vitro response to phytohemagglutinin (PHA) could partly be restored, and skin tests revealed improved response to recall antigens. These findings indicate that IL-2 can be administered safely and effectively by the intralymphatic route and may--in addition to antibiotics--be of value in AIDS patients with severe opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495696     DOI: 10.1007/BF01745579

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

Review 2.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

3.  Immunologic characterization of a helper T-cell lymphoma.

Authors:  M Gramatzki; M F Dolan; A S Fauci; J A Maples; G D Bonnard; D M Strong
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

4.  Strategies for generating monoclonal antibodies defining human t-lymphocyte differentiation antigens.

Authors:  P C Kung; M A Talle; M E DeMaria; M S Butler; J Lifter; G Goldstein
Journal:  Transplant Proc       Date:  1980-09       Impact factor: 1.066

5.  Pneumocystis carinii pneumonia among persons with hemophilia A.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1982-07-16       Impact factor: 17.586

6.  Cryopreserved human cultured T cells as responder cells for the quantitative measurement of interleukin-2: improvement of the assay.

Authors:  M Gramatzki; D M Strong; S B Grove; G D Bonnard
Journal:  J Immunol Methods       Date:  1982-09-17       Impact factor: 2.303

7.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Immunologic effects of interleukin 2 in primary immunodeficiency diseases.

Authors:  N Flomenberg; K Welte; R Mertelsmann; N Kernan; N Ciobanu; S Venuta; S Feldman; G Kruger; D Kirkpatrick; B Dupont; R O'Reilly
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Identification of a human T lymphocyte surface protein associated with the E-rosette receptor.

Authors:  M Kamoun; P J Martin; J A Hansen; M A Brown; A W Siadak; R C Nowinski
Journal:  J Exp Med       Date:  1981-01-01       Impact factor: 14.307

View more
  1 in total

1.  Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS.

Authors:  T Harrer; J Schwab; W G Struff; M Schmitt; J H Ficker; W Rödl; H Parsch; J R Kalden; M Gramatzki
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.